Treatment of diffuse large B-cell lymphoma: a risk-based approach
- PMID: 17101068
- DOI: 10.3816/clm.2006.s.003
Treatment of diffuse large B-cell lymphoma: a risk-based approach
Abstract
Advances in molecular biology have provided an increased understanding of the heterogeneity of diffuse large B-cell lymphoma, allowing multiple clinical and biologic prognostic factors to be elucidated. Recently, the addition of rituximab to CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) has been adopted as the new standard of care, representing the first major improvement in therapy in 2 decades. Although outcomes have markedly improved, patients with lymphoma that is not cured with this standard first-line therapy continue to pose a difficult challenge. Early identification of patients at high risk would allow alternative treatment strategies to be considered in a risk-based management approach. Accurate risk assessment will require all previously recognized prognostic indicators to be revalidated in the era of immunochemotherapy. Although the International Prognostic Index remains predictive, it no longer distinguishes a subgroup with < 50% chance of survival. Many molecular prognostic markers, such as Bcl-2 and Bcl-6 protein expression, no longer appear predictive of outcome. Early positron emission tomography scanning is a powerful independent predictive tool that will likely be relied on more frequently in the future. Finally, the role of increased dose intensity or dose density will need to be reevaluated for combinations that include rituximab. Alternative treatment strategies and newer therapies will need to be explored in the context of clinical trials.
Similar articles
-
Diffuse aggressive lymphoma.Hematology Am Soc Hematol Educ Program. 2004:221-36. doi: 10.1182/asheducation-2004.1.221. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561685 Review.
-
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28. Lancet Oncol. 2017. PMID: 28668386 Clinical Trial.
-
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22. Lancet. 2013. PMID: 23615461 Clinical Trial.
-
Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.Histopathology. 2013 Dec;63(6):788-801. doi: 10.1111/his.12223. Epub 2013 Oct 1. Histopathology. 2013. PMID: 24117687
-
Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.Semin Oncol. 2003 Feb;30(1 Suppl 2):21-7. doi: 10.1053/sonc.2003.50021. Semin Oncol. 2003. PMID: 12652461 Review.
Cited by
-
Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.Leukemia. 2015 Sep;29(9):1857-67. doi: 10.1038/leu.2015.86. Epub 2015 Mar 24. Leukemia. 2015. PMID: 25801911 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials